3550 General Atomics Court
Building 2, Room 503
141 articles with ViaCyte, Inc.
In a recent interview with BioSpace, Imagine Pharma CEO Ngoc Thai shared the vast potential posed by a polypeptide called IMG-1 to treat Type 1 diabetes.
Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
CRISPR Therapeutics reported in its first-quarter financials, as of March 31, it had $2.221 billion in cash, cash equivalents and marketable securities to drive its progress.
ViaCyte to Participate in 2022 Advanced Technologies & Treatments for Diabetes Conference
Manasi Sinha Jaiman, M.D., M.P.H., who was recently appointed Chief Medical Officer at Viacyte Inc., will participate in the 15th International Conference on Advanced Technologies & Treatments for Diabetes' (ATTD) session, Utility of PROs in Therapy Development for Type 1 Diabetes: Putting the End-User Upfront.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
CRISPR Therapeutics and ViaCyte, Inc., today announced the first patient has been dosed in the Phase 1 clinical trial of VCTX210.
ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of Directors
ViaCyte, Inc. today announced the appointment of Alyssa Levin as Chief Financial Officer and addition of Lisa E. Porter, M.D., to its Board of Directors.
ViaCyte Chief Scientific Officer to Deliver Keynote Address at JDRF Mission Summit
ViaCyte, Inc. announced today that the Company's Chief Scientific Officer, Timothy Kieffer , Ph.D., will deliver the keynote address at the 10th JDRF Mission Summit.
ViaCyte's Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studies
ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with significant unmet needs, announced publication of promising preliminary results of an ongoing, first-in-human Phase 1/2 study demonstrating that its stem cell-derived therapy can produce insulin in people with severe type 1 diabetes (T1D).
ViaCyte Appoints Marty Lorenzo as General Counsel
ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, announced the appointment of Marty Lorenzo as General Counsel.
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes-Initiation of patient enrollment expected by year-end-
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced that Health Canada has approved the companies’ Clinical Trial Application (CTA) for VCTX210,
ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit
ViaCyte, Inc. will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m. ET
ViaCyte to Participate in International Pancreas & Islet Transplantation Association Virtual Congress
Evert Kroon , Ph.D., Vice President of Translation Research at ViaCyte, Inc. will participate in the International Pancreas & Islet Transplantation Association (IPITA) Virtual Congress' session, " Islet Organoids From Pluripotent and Adult Stem Cells " on Friday, October 22, 2021 from 8:05-9:05 a.m. ET.
ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa
ViaCyte, Inc. announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021 , at 10:15 a.m. PT in Carlsbad, CA.
ViaCyte Appoints Stem Cell Therapy Expert Dr. Timothy Kieffer as Chief Scientific Officer
ViaCyte, Inc., an innovator in cellular therapy and regenerative medicine, today announced the appointment of Timothy Kieffer, Ph.D., as Chief Scientific Officer.
BioSpace Movers & Shakers, July 23
7/23/2021Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
ViaCyte Appoints Dr. Jon Wilensky as Head of Surgery
ViaCyte, Inc., an innovator in cellular therapy and regenerative medicine, announced that it has appointed Jon Wilensky, MD, MBA, FACS, as Head of Surgery.
ViaCyte Reports Compelling Preliminary Clinical Data from Islet Cell Replacement Therapy for Patients with Type 1 Diabetes
ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with insulin-requiring diabetes, announced today compelling preliminary clinical data from its stem cell-derived islet cell replacement therapy for patients with type 1 diabetes (T1D).